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Abstract
Background: Pancreatic cancer is one of the most aggressive human malignancies. The development of a novel
drug to treat pancreatic cancer is imperative, and it is thought that complementary and alternative medicine (CAM)
could yield such a candidate. Agaricus blazei Murrill is a CAM that has been tested as an anticancer drug, but its
efficacy against pancreatic cancer is poorly understood. To study the potential of A. blazei in the treatment of
pancreatic cancer, we examined the effects of its hot water extract on the proliferation and global gene expression
profile of human pancreatic cancer cells.
Methods: Three distinct human pancreatic cancer cell lines, MIAPaCa-2, PCI-35, and PK-8, and the immortalized
human pancreatic duct-epithelial cell line, HPDE, were employed. The cells were incubated with the appropriate
growth medium supplemented with the hot water extract of A. blazei at final concentrations of 0.005, 0.015%, or 0.
045%, and cellular proliferation was assessed for five consecutive days using an MTT assay. Apoptosis was examined
by using flow cytometry and the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay.
Caspase-dependent apoptosis was assayed using immunoblotting. Global gene expression profiles were examined
using a whole human genome 44 K microarray, and the microarray results were validated by using real-time reverse
transcription PCR.
Results: The hot water extract of A. blazei significantly inhibited the proliferation of cultured pancreatic cancer cells
through the induction of G0/G1 cell cycle arrest and caspase-dependent apoptosis; the effect was the smallest in
HPDE cells. Furthermore, significant alterations in the global gene expression profiles of pancreatic cancer cells
occurred following treatment with the hot water extract of A. blazei. Genes associated with kinetochore function,
spindle formation, and centromere maintenance were particularly affected, as well as cyclins and cyclin-dependent
kinases that are essential for cell cycle progression. In addition, proapoptotic genes were upregulated.
Conclusions: The hot water extract of A. blazei may be useful for the treatment of pancreatic cancer and is a
potential candidate for the isolation of novel, active compounds specific for mitotic spindle dysfunction.
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Background
In 2012, pancreatic cancer was estimated to be the twelfth
most common cancer in men and the eleventh most com-
mon in women, with an estimated 330,000 deaths occur-
ring worldwide. Because of this very high mortality rate,
comprising an overall mortality-to-incidence ratio of 0.98
and a 5-year survival rate of 5%, pancreatic cancer ranks
as the seventh most common cause of death from cancer
worldwide. The leading identified cause of pancreatic can-
cer is cigarette smoking, but other risk factors include
older age, race, obesity, diabetes mellitus, and chronic
pancreatitis [1]. The signs and symptoms of pancreatic
cancer include back pain, unexplained weight loss, jaun-
dice, and pruritus. New-onset diabetes can be the first
manifestation of pancreatic cancer [2]. The most effective
therapeutic option for pancreatic cancer is a curative
surgical resection with adjuvant chemotherapy; however,
only 15–20% of pancreatic cancer patients are candidates
for surgery/chemotherapy. After this curative operation,
the 5-year survival rate approaches 20% [3].
Gemcitabine has been a systemic first-line chemother-
apeutic drug for pancreatic cancer patients for nearly
two decades; however, it has limited efficacy and the
mean survival period is only 6 months [4]. Recently, two
randomized controlled trials showed a moderate advan-
tage of combination therapies over gemcitabine: FOL-
FIRINOX (folinic acid, 5-fluorouracil, irinotecan, and
oxaliplatin) prolonged patient survival to 11.1 months
(vs. 6.8 months with gemcitabine alone) [5], and gemci-
tabine plus nab-paclitaxel prolonged survival to 8.5
months (vs. 6.7 months with gemcitabine alone) [6].
However, most patients experienced relapses, although
they managed to tolerate the increased drug toxicity.
Therefore, it is imperative to find a novel compound for
the treatment of pancreatic cancer that is more effective
and has a lower burden of toxicity.
Complementary and alternative medicine (CAM) has
been used for the treatment of numerous chronic
disease conditions, including cancer [7]. Mushrooms are
the most frequently used CAM in Japan, with Agaricus
blazei Murrill, a medicinal mushroom commonly known
as “Himematsutake,” accounting for 60.6% of the medi-
cinal mushroom usage in Japan. A. blazei has been
tested for the treatment of cancer, viral diseases, and dia-
betes mellitus [8–13]. We previously found that a hot
water extract of A. blazei (AbE) could improve cardio-
vascular symptoms in patients; subsequently, we found
that brefeldin A, a compound purified from AbE, had es-
trogenic activity [14, 15]. Experiments have confirmed the
ability of AbE to inhibit the growth of various cancers, in-
cluding colon cancer, leukemia, methylcholanthrene-
induced fibrosarcoma, Sarcoma-180, Ehrlich ascites car-
cinoma, and Shionogi carcinoma [16–19]. AbE was shown
to induce apoptosis in cancer cells through the Bax- and
the caspase-dependent pathway and to modulate im-
munological reactions through an increase in the produc-
tion of tumor necrosis factor-α (TNF-α) and interleukin-8
(IL-8) by macrophages [20–22]. Despite these studies, the
detailed mechanistic pathways of these pharmaceutical ef-
fects remain unknown. Moreover, despite the current
prevalence of genomic investigations in scientific research,
the effect of AbE on global gene expression in human cells
has not been investigated.
To determine the potential of AbE for the treatment of
pancreatic cancer, we compared its effects on the prolifera-
tion of human pancreatic cancer cells and normal
pancreatic duct-epithelial cells. Moreover, to gain mechan-
istic insight into the effects of AbE, we explored the global




A. blazei powder (A. blazei mycelia-dikaryon, strain
my26) was provided by JMCU Center Corporation [14].
The powder (2.5 g) was boiled in 45mL water for 10
min. The supernatant was recovered by centrifugation at
3300×g for 3 min and sterilized by filtration through a
0.22-μm membrane. The solution obtained (AbE) was
used for the following experiments.
Cell culture
Three human pancreatic cancer cell lines, MIA PaCa-2,
PCI-35, and PK-8, and the immortalized human pancre-
atic duct epithelial cell line, HPDE, were used in this
study. MIA PaCa-2 was purchased from American Type
Culture Collection (Manassas, VA, USA). PCI-35 was
obtained from Dr. Hiroshi Ishikura at Department of
Pathology, Hokkaido University Graduate School of Medi-
cine, Sapporo, Japan [23]. PK-8 was obtained from Dr.
Masao Kobari at the Department of Surgery, Tohoku Uni-
versity Graduate School of Medicine, Sendai, Japan [24].
HPDE was obtained from Dr. Ming-Sound Tsao, Depart-
ment of Pathology, Princess Margaret Hospital and To-
ronto University, Toronto, Canada [25]. PCI-35 and PK-8
were cultured in RPMI 1640 (Sigma-Aldrich Corp., St.
Louis, MO, USA) supplemented with 10% fetal bovine
serum (Biowest, Nuaillé, France). MIA PaCa-2 was cul-
tured in DMEM (Sigma-Aldrich Corp.) supplemented
with 10% fetal bovine serum (Biowest). HPDE was main-
tained in Medium 154 (Cascade Biologics, Portland, OR,
USA) containing 1% human keratinocyte growth supple-
ment (Cascade Biologics). All cells were maintained at 37 °
C in a humid atmosphere with 5% CO2.
Cell proliferation assay
For this assay, 5000 cells/well were plated in 100 μL of
the appropriate culture medium in 32 wells of a 96-well
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plate; in total, 5 plates were used. The cells were incu-
bated for 24 h and then the culture medium of 8 wells
was replaced with medium supplemented with AbE at
final concentrations of 0.005, 0.015%, or 0.045% (w/v).
For the control (MOCK), an equal volume of water was
added to the medium of the remaining 8 wells. On each
assay day, the medium from each of the 32 wells in one
plate was replaced with 100 μL of 0.05% 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)/PBS(−), and the plate was then incubated for 1 h
at 37 °C in an atmosphere containing 5% CO2. After in-
cubation, the MTT solution was removed by aspiration,
the cells were resuspended in 100% ethanol, and the ab-
sorption of the ethanol solution at 590 nm was mea-
sured. The process was repeated for each plate on
consecutive days. The 50% growth inhibitory concentra-
tion (GI50) values were calculated from the percentage
of surviving cells after AbE treatments of 0, 0.00057,
0.0017, 0.005, 0.0085, 0.015, 0.026, and 0.045% by a
four-parameter logarithmic method using GraphPad
Prism 6 (GraphPad Software Inc., La Jolla, CA, USA).
Flow cytometry
The cells were plated in the appropriate culture medium
at a density of 2.5 × 105 cells/plate in 10-cm dishes. After
incubation for 24 h, the cells were treated with 0.005,
0.015%, or 0.045% (w/v) AbE for 48 h. For the control
(MOCK), an equal volume of water as AbE supplement
was added to the medium. The cells were washed with
PBS(−) and fixed overnight with 70% ethanol at − 20 °C.
The fixed cells were resuspended in 100 μL hypotonic
citrate buffer (192mmol/L Na2HPO4, 4 mmol/L citric
acid) and incubated for 20 min at room temperature.
The cells were then pelleted and resuspended in PI/
RNase/PBS (100 μg/mL propidium iodide and 10 μg/mL
RNase A in PBS). DNA content was analyzed using
the FACSCalibur™ System (BD Biosciences, San Diego,
CA, USA).
Terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL) assay
The cells were plated using the appropriate culture
medium at a density of 2.5 × 105 cells/plate in 10 cm
dishes. After incubation for 24 h, the cells were treated
with 0.045% (w/v) AbE. For the control, an equal volume
of water was added to the medium of the MOCK cells.
After incubation for 48 h, the floating and adherent cells
were collected and fixed with 4% paraformaldehyde/PBS
overnight at 4 °C. The cells were washed with PBS and
then spread on MAS-coated glass slides (Matsunami
Glass Industry Ltd., Tokyo, Japan). The TUNEL assay
was performed to identify DNA fragmentation in situ by
using a FragEL™ DNA fragmentation Detection Kit,
Colorimetric-TdT Enzyme (Calbiochem, San Diego, CA,
USA) in accordance with the manufacturer’s protocol.
Approximately 500 cells from randomly selected fields
were observed at 400× magnification, from which the
number of TUNEL-positive cells was counted.
Microarray
Total RNA was extracted from cells treated with 0.045%
(w/v) AbE or water for 48 h by using the RNeasy Midi
Kit (QIAGEN, Hilden, Germany) in accordance with the
supplier’s instructions. The extraction was repeated in-
dependently in triplicate. cRNAs labeled with Cyanine 3
were synthesized via the T7-linear amplification method
from 500 ng of total RNA using the Low RNA Input
Linear Amplification Kit (Agilent Technologies, Palo
Alto, CA, USA), and subsequently purified by using the
RNeasy Mini Kit (QIAGEN). For each hybridization,
1.65 μg of cRNAs was fragmented at 60 °C for 30 min
using the Gene Expression Hybridization Kit (Agilent
Technologies) and hybridized at 65 °C for 17 h to a 4 ×
44 K Whole Human Genome Microarray slide (Agilent
Technologies) in accordance with the manufacturer’s
instructions. The microarrays were scanned and the sig-
nals in the scanned image were converted to intensity
values that were subsequently normalized by software
provided by Hokkaido System Science Co., Ltd. (Sap-
poro, Japan). The expression levels were normalized to
the 75th percentile, and baseline transformations were
conducted by using the median of the control samples
from each cell line. As a means of quality control, the
correlation coefficients were analyzed; one sample of
PK-8 cells treated with AbE was excluded because its
correlation coefficient with the other replicates was
below 0.01. Lists of genes with greater than four-fold
change in expression were identified by t-test (P < 0.05)
using R (https://www.r-project.org/). Gene Ontological
category lists containing genes with statistically signifi-
cant expression levels were obtained using Fisher’s exact
tests, using Benjamini-Yekutieli corrections (P < 0.05).
The whole microarray data set was deposited to
Gene Expression Omnibus (https://www.ncbi.nlm.-
nih.gov/geo/) under the accession number
GSE89396. Over-representation analyses were per-
formed using online the programs of PANTHER
(http://www.pantherdb.org) [26] and REACTOME
(https://www.reactome.org) [27].
Immunoblotting
Pancreatic cancer cells treated with 0.045% (w/v) AbE or
an equal volume of water for 48 h were harvested by
mild scraping, centrifuged, and washed with ice-cold
PBS(−) containing Complete Mini protease inhibitors
(Roche, Basel, Switzerland). The cells were then sus-
pended in an appropriate volume of RIPA buffer (Sig-
ma-Aldrich) plus protease inhibitors (Roche) and lysed
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by sonication. The lysates (120 mg) were denatured, sep-
arated on SDS-polyacrylamide gels (Bio-Rad, Hercules,
CA, USA), and then electroblotted onto Clear Blot
membrane-p (ATTO, Tokyo, Japan). An SDS gradient
gel of 5–20% polyacrylamide was used for poly (ADP-ri-
bose) polymerase 1 (PARP1) and 10–20% polyacrylamide
was used for caspase-3, caspase-9, and β-actin. After
non-specific binding to the membrane was blocked by
incubation with TBST (20 mM Tris-HCl, pH 7.6, 137
mM NaCl, and 0.1% Tween® 20) containing 5% (w/v)
Amersham ECL Blocking Agent (GE Healthcare UK
Ltd., Buckinghamshire, UK), the membranes were incu-
bated overnight at 4 °C with Can Get Signal® Solution 1
(TOYOBO, Osaka, Japan) containing the following anti-
bodies, separately: mouse monoclonal anti-PARP1 (clone
42/PARP, dilution 1:125, BD Biosciences, San Jose, CA,
USA), mouse monoclonal anti-caspase-3 (clone 3G2, di-
lution 1:1000, Cell Signaling Technology Inc., Beverly,
MA, USA), rabbit polyclonal anti-caspase-9 (dilution
1:1000, Cell Signaling Technology Inc.), or mouse mono-
clonal anti-β-actin (clone AC-15, dilution 1:1000,
Sigma-Aldrich). Then, the membranes were incubated
with Can Get Signal® Solution 2 (TOYOBO) containing
an appropriate horseradish peroxidase (HRP)-conjugated
anti-mouse or anti-rabbit immunoglobulin secondary
antibody (dilution 1:10000, GE Healthcare UK Ltd.) at
room temperature for 1 h. The bound antibodies were
detected by the application of enhanced chemilumines-
cence (ECL) solution (Amersham ECL Plus™ Western
Blotting Detection Reagents, GE Healthcare UK Ltd.)
and digitally processed using an LAS-4000 mini image
analyzer (Fuji Photo Film Co. Ltd., Minamiashigara,
Japan).
Quantitative reverse transcription PCR
Single-stranded cDNA was synthesized from the total
RNA used for the microarray analysis using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) in accordance with
the manufacturer’s instructions. Quantitative PCR was
performed using the 7500 Real-Time PCR System (Ap-
plied Biosystems) with the synthesized cDNAs and
Pre-Developed TaqMan® Assay Reagents (Applied Bio-
systems) for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; 4326317E) or TaqMan® Gene Expression As-
says (Applied Biosystems) for cyclin D1 (CCND1;
Hs00277039_m1), cyclin-dependent kinase inhibitor 3
(CDKN3; Hs00193192_m1), cyclin B2 (CCNB2;
Hs00270424_m1), cyclin A2 (CCNA2; Hs00996789_g1),
cyclin F (CCNF; Hs00171049_m1), CHK2 checkpoint
homolog (S. pombe) (CHEK2; Hs00200485_m1), ataxia
telangiectasia mutated (ATM; Hs00175892_m1), cell div-
ision cycle 25 homolog A (S. pombe) (CDC25A;
Hs00153168_m1), breast cancer 1, early onset (BRCA1;
Hs00173237_m1), high mobility group (HMG)-box tran-
scription factor 1 (HBP1; Hs00202110_m1), forkhead box
O4 (FOXO4; Hs00172973_m1), vasohibin 1 (VASH1;
Hs00208609_m1), BRCA1 associated RING domain 1
(BRAD1; Hs00184427_m1), cyclin-dependent kinase 6
(CDK6; Hs00608037_m1), NLR family pyrin domain
containing 1 (NLRP1; Hs00248187_m1), death effector do-
main containing 2 (DEDD2; Hs00370206_m1), or death-
associated protein kinase 3 (DAPK3; Hs00154676_m1).
The PCR cycling program consisted of 95 °C for 10min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1min.
All samples were analyzed in triplicate and gene expression
was calculated relative to the reference housekeeping gene,
GAPDH.
Results
AbE attenuates proliferation of human pancreatic cancer
cells
First, we explored the effect of AbE on the proliferation
of human pancreatic cancer cells of genetically and his-
tologically distinct origins: MIA PaCa-2, PCI-35, and
PK-8 [28]. The cells were incubated with appropriate
growth medium supplemented with AbE at final concen-
trations (w/v) of 0.005, 0.015%, or 0.045%, and cellular
proliferation was then monitored for five consecutive
days by using the MTT assay. We found that AbE sig-
nificantly attenuated proliferation of all the pancreatic
cancer cell lines in a concentration-dependent manner
(Fig. 1a-c). Although the effect of 0.005% AbE was mild,
0.015% AbE was sufficient to induce almost complete
blockage of cell proliferation in all three cell lines. To
compare the effect of AbE on pancreatic cancer cells
with its effect on normal pancreatic ductal cells, we
treated an immortalized human pancreatic duct epithe-
lial cell line, HPDE [25], with AbE under the same
conditions. The results revealed that HPDE was less
sensitive, i.e., more resistant, to AbE than pancreatic
cancer cell lines (Fig. 1d, e). The GI50 values of AbE
treatment for the tested cell lines were 0.015% for MIA
PaCa-2, 0.012% for PCI-35, 0.009% for PK-8, and 0.094%
for HPDE. These results indicated that AbE significantly
and specifically inhibited the proliferation of pancreatic
cancer cells relative to that of normal duct-epithelial
cells.
AbE induces apoptotic cell death in pancreatic cancer
cells
To elucidate the mechanism of the inhibition of cell pro-
liferation, we used flow cytometry to quantify the cell
cycle phase distribution and the sub-G1 DNA content of
pancreatic cancer cells treated with AbE for 48 h. The
treatment significantly increased the proportion of cells
in the G1 or G2 fraction, with a variable increase in the
population of the sub-G1 fraction, which indicated that
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AbE induced G1 or G2 arrest and apoptosis in pancre-
atic cancer cells (Fig. 2). Morphological examination of
nuclei stained with DAPI (4′,6-diamidino-2-phenylin-
dole) revealed increased nuclear fragmentation in
AbE-treated cells compared with control-treated cells
(Fig. 3). TUNEL assays demonstrated that the number of
TUNEL-positive cells actually increased after AbE treat-
ment (Fig. 3). These results provided further evidence
that AbE induces apoptotic cell death of pancreatic can-
cer cells.
To determine whether the AbE-induced apoptosis was
caspase-dependent, the cleavage of caspase-3, caspase-9,
and PARP1 was examined: AbE treatment induced
cleavage of these molecules, which indicated that AbE
induces apoptosis through the caspase-dependent path-
way (Fig. 4).
Fig. 1 a-d Attenuation of the proliferation of human pancreatic cancer cells compared with that of human normal pancreatic duct epithelial (HDPE)
cells by hot water extract of Agaricus blazei Murrill (AbE). Relative proliferation of pancreatic cancer cell lines (MIA PaCa-2, PCI-35, and PK-8) and HPDE
treated with AbE at the indicated concentrations, measured by using the MTT assay. The plots represent the average of eight replicates, and the error
bars indicate the standard deviation. Y axis denotes a relative growth rate to the mean value of MOCK on Day 1. e Cell death curves of pancreatic
cancer cells and HPDE cells treated for 48 h with serial dilutions of AbE. An unpaired t-test with the Holm-Sidak method for multiple comparisons
correction was used to compare HPDE to pancreatic cancer cells. ***p < 0.001
Fig. 2 Hot water extract of Agaricus blazei Murrill (AbE) induces cell cycle arrest and apoptosis in pancreatic cancer cells. A. Flow cytometric
analysis of the cell cycle phase fractions of pancreatic cancer cells (MIA PaCa-2, PCI-35, and PK-8) and the human normal pancreatic duct
epithelial (HDPE) cells treated with AbE at the indicated concentrations for 48 h. B. A plot of the relative number of cells in cell cycle fractions
including sub-G1 fraction after 0.045% AbE treatment, obtained using flow cytometric analysis
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Alteration of global gene expression by AbE treatment in
pancreatic cancer cells
To determine the effect of AbE on gene expression in
human pancreatic cancer cells, global gene-expression
profiles were investigated using a whole human genome
microarray. The data of the microarray results were de-
posited at the Gene Expression Omnibus (https://
www.ncbi.nlm.nih.gov/geo/) under the accession number
Fig. 3 Pancreatic cancer cells treated with hot water extract of Agaricus blazei Murrill (AbE) undergo apoptotic cell death. a DAPI staining indicates
fragmented nuclei in AbE-treated cells (arrows). b In situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay
indicating DNA fragmentation in AbE-treated cells. c The number of TUNEL-positive cells increased with AbE treatment. ***p < 0.001
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GSE89396. We focused on genes with at least a statis-
tical significantly four-fold change in expression follow-
ing AbE treatment, and then performed Venn diagram
analysis. Of the examined genes, 394 were commonly
altered in all pancreatic cancer cells, of which 210 were
downregulated and 184 were upregulated (Fig. 5a,
Additional file 1: Table S1). The PANTHER statistical
over-representation test based on the Gene Ontology
(GO) database (http://www.pantherdb.org/; released
2016-09-24) was conducted to investigate the functional
aspects of the commonly altered genes (Additional file 2:
Table S2). In the analysis using the GO biological
process database, the genes significantly overrepresented
were associated with the kinetochore, spindle check-
point, mitotic prometaphase, centromere protein A
(CENP-A)-containing nucleosome assembly, mitotic
cytokinesis, G2 DNA damage checkpoint, sister chroma-
tid cohesion, regulation of mitotic metaphase/anaphase
transition, mitotic sister chromatid segregation, regula-
tion of the G2/M transition of mitotic cell cycle, mitotic
anaphase, establishment of chromosome localization,
mitotic cell cycle checkpoint, negative regulation of
mitotic cell cycle phase transition, and positive regula-
tion of cell cycle process (Additional file 3: Table S3). In
the analysis using the GO molecular function database,
genes associated with protein binding were significantly
overrepresented (Additional file 3: Table S3). In the ana-
lysis using the GO cellular component database, genes
associated with Ndc80 complex, spindle midzone,
midbody, and spindle pole were significantly overrepre-
sented (Additional file 3: Table S3). We also performed
another over-representation test using REACTOME and
confirmed that genes associated with the mitotic spindle
checkpoint were significantly overrepresented (p =
3.19E-8; Additional file 4: Table S4). We performed an
additional analysis to see if any genes were specifically
overrepresented in a particular cell line, but we did not
find any such genes.
Then, we analyzed genes specifically altered in each
cell line by AbE treatment because each cell responded
differently; in detail, MIA PaCa-2 showed marked G2 ar-
rest and apoptosis; PCI 35 showed G1 arrest and apop-
tosis; and PK-8 showed less significant G1 arrest and
apoptosis (Fig. 2). As shown in Fig. 5, 594, 691, and
1709 genes were specifically altered 4-fold in MIA
PaCa-2, PCI-35, and PK-8, respectively. Among them,
297, 361, and 888 genes were annotated by GO Bio-
logical Process in MIA PaCa-2, PCI35, and PK-8, re-
spectively. Each had unique genes associated with cell
cycle, cell cycle arrest, G1 phase, G2 phase, and apop-
tosis (Additional file 5: Table S5).
We validated the alterations in expression of genes as-
sociated with cell cycle, namely CCND1, VASH1,
CCNA2, CCNB2, HBP1, BARD1, CCNF, CDK6, and
FOXO4, and those associated with apoptosis, namely
DEDD2, DAPK3, and NLRP1, by using the quantitative
reverse transcription PCR [29–34]. The validation con-
firmed the downregulation of cell cycle-promoting genes
(CCND1, CCNA2, CCNB2, BARD1, CCNF, and CDK6)
and the upregulation of cell cycle arrest genes (VASH1
and HBP1) and proapoptotic genes (DEDD2, DAPK3,
and NLRP1) in all cell lines tested in this study (Fig. 5b).
These results of global gene expression analyses indi-
cated that AbE treatment impaired kinetochore function,
spindle formation, centromere maintenance, cyclins, and
cyclin-dependent kinases, which are essential for cell
cycle progression.
Discussion
In this study, we revealed that AbE treatment attenuated
the proliferation and induced caspase-dependent apop-
totic cell death of human pancreatic cancer cells. The at-
tenuation of cell proliferation was less remarkable in
cells from the normal pancreatic duct. Moreover, we
found that AbE treatment drastically altered the expres-
sion of genes mainly associated with kinetochore func-
tion, mitosis, and cell cycle progression. These results
indicated that AbE may be useful for the treatment of
pancreatic cancer and serve as a candidate for isolation
of novel chemical compounds that specifically alter spin-
dle function.
From our analysis of the effect of AbE on the global
gene expression of human pancreatic cancer cells, AbE
seems to repress genes specifically associated with
kinetochore function, spindle formation, centromere
maintenance, and regulation of cyclins. CASC5 encodes
the protein, kinetochore scaffold 1, which is a compo-
nent of the multiprotein assembly required for the for-
mation of kinetochore-microtubule attachments and
Fig. 4 Hot water extract of Agaricus blazei Murrill (AbE) induces
caspase-dependent apoptosis. Immunoblots indicate the expression
of caspase-3 (CASP3), caspase-9 (CASP9), poly (ADP-ribose)
polymerase (PARP), and their active cleaved products.
Immunostaining for β-actin was used as the loading control
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chromosome segregation. BUB1 and BUB1B encode the
proteins, BUB1 mitotic checkpoint serine/threonine kin-
ase and BUB1 mitotic checkpoint serine/threonine kin-
ase B, respectively; these function by phosphorylating
the members of the mitotic checkpoint complex and ac-
tivating the spindle checkpoint. PLK1 encodes the pro-
tein, polo like kinase 1, which participates in DNA
replication and repair, cell cycle progression, centriole
duplication, and centrosome maturation [35]. AURKB
encodes the protein, aurora kinase B, which participates
in the regulation of alignment and segregation of chro-
mosomes during mitosis and meiosis through associ-
ation with microtubules. KNTC2 encodes a component
of the Ndc80 kinetochore complex that organizes and
stabilizes microtubule-kinetochore interactions and is
required for proper chromosome segregation. ZWINT
encodes the ZW10 interacting kinetochore protein that
is possibly involved in kinetochore function via the regu-
lation of the association between ZW10 and kineto-
chores. CENPA, CENPE, CENPF, CENPI, CENPU/
Fig. 5 a Venn diagram analysis of global gene expression of pancreatic cancer cells treated with the hot water extract of Agaricus blazei Murrill
(AbE). Genes with a statistically significant (greater than four-fold) change in expression were collected and classified. In the three cell lines, 394
genes were commonly altered. b Quantitative reverse transcription PCR was performed to validate the microarray results. The expression of genes
associated with cell cycle progression or apoptosis was altered by the AbE treatment. The mean changes in gene expression relative to those in
untreated cells, calculated by using GAPDH as the reference housekeeping gene, are displayed on a log2 scale. The difference in expression of
each mRNA relative to that of non-treated cells was determined using a Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001
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MLF1IP, and CENPW/C6orf173 encode centromere pro-
teins that are vital for centromere functions. CCNA2,
CCNB2, and CCND1 encode cyclins, and CDC2/CDK1,
CDC7, CDC20, and CDCA2 encode cell division cycle
proteins that are required for progression of the cell
cycle. HBP1 encodes the HMG-box transcriptional fac-
tor 1 that represses the function of CCND1 [36]. CIT
encodes the citron rho-interacting serine/threonine kin-
ase that is active in cell division.
Apoptosis is a biological process that eliminates re-
dundant, damaged, or infected cells [37]; apoptotic path-
ways are disrupted in many cancers. Moreover, these
disrupted apoptotic pathways are associated with the
chemoresistance of pancreatic cancer [38]. Our analyses
of the pancreatic cancer cells treated with AbE consist-
ently showed that they led to apoptotic cell death that
depended on caspase activation. Caspases are critical
components of apoptosis and are activated by proteolytic
cleavage. Caspase-3 is one of the central effector cas-
pases for both the intrinsic and extrinsic apoptotic path-
ways. Caspase-3 is activated by the caspase-9 apoptosome
in the intrinsic pathway, and it cleaves PARP1 into 24 kDa
and 89 kDa fragments, leading to inhibition of DNA repair
enzymes. We also showed that the genes encoding proa-
poptotic proteins, namely DEDD2, DAPK3, and NLRP1,
were overexpressed in pancreatic cancer cell lines treated
with AbE. Overexpression of DEDD2 can induce apoptosis
by binding and activating caspase-8/caspase-10, and
sensitizing cells to apoptosis triggered by CD95 or tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)
[29, 30]. DAPK3 is a p53-activating kinase and overexpres-
sion of DAPK3 can lead to apoptosis [31, 32]. DAPK3 is
required for caspase activation together with death-domain
associated protein (DAXX) [33]. NLRP1 overexpression
can also induce apoptosis in breast adenocarcinoma cells
[34]. Among the genes repressed by AbE treatment, GTSE1
encodes the protein G2 and S-phase expressed 1 (GTSE1),
which is only expressed in the S and G2 phases of the cell
cycle, where it colocalizes with cytoplasmic tubulin and mi-
crotubules. It has been reported that GTSE1 accumulates
in the nucleus in response to DNA damage and binds p53,
shuttling the latter out of the nucleus and suppressing its
ability to induce apoptosis [39]. Given that the p53 pathway
commonly malfunctions in pancreatic cancer, and that p53
is often disrupted in pancreatic cancer cells by mutation or
loss of expression [28], it is remarkable that AbE can induce
apoptotic cell death in such cells.
In contrast, the cells responded differently to AbE.
MIA PaCa-2 showed G2 arrest and apoptosis,
whereas PCI-35 and PK-8 showed mainly G1 arrest.
We analyzed genes potentially associated with these
cell-specific characteristic features, which included
many genes associated with cell cycle arrest and
apoptosis (Additional file 5: Table S5).
The isolation of active compounds from natural prod-
ucts is a classic and powerful method for the discovery
of new efficacious treatments for disease. Several com-
pounds have been isolated from AbE that showed antitu-
mor activity [9, 40–42]: polysaccharides, agaritine, and a
phenylhydrazine containing a glutamyl residue. The
compounds responsible for the impairment of mitotic
spindle function that can induce apoptotic cell death in
pancreatic cancer cells should be identified.
Conclusion
The results of this study indicate that the hot water ex-
tract of A. blazei could be useful for the treatment of
pancreatic cancer and is a potential candidate for the
isolation of novel active compounds to impair mitotic
spindle function.
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